BPm-Health Handset

Self-monitoring of blood pressure during pregnancy

BPm-Health

Self-monitoring of blood pressure during pregnancy

The Blood Pressure management system BPm-Health allows pregnant women to self-monitor blood pressure during pregnancy and enables healthcare professionals to provide remote care for mums-to-be.

Get it on Google PlayDownload on the App Store

The need for safe remote monitoring during the COVID-19 epidemic

There has been an increasing recognition of the benefits from self-monitoring of blood pressure (‘BP’) during pregnancy - see references below.  The COVID-19 outbreak is now increasing the need for healthcare professionals to advocate BP self-monitoring to reduce face-to-face consultations for pregnant and postnatal women whilst maintaining care for the woman and her baby.

Sensyne Health is working with the NHS to expand the use of the product across the UK, offering BPm-Health FREE of charge for 1 year in response to the COVID-19 pandemic.

Find out more

Self-monitoring in pregnancy

Either to replace BP measurements on the day of a clinic or so that BP measurements may be done more frequently.

Easy to use

Provides an easy to use system for women, many of whom already informally self-monitor.

Provides advice

Provides advice on what a woman should do depending on her BP levels.

BPm-Health is aimed at:

Pregnancy

Women with chronic hypertension, gestational hypertension, pre-eclampsia

Pregnancy

Women determined as high or moderate risk by NICE guidelines (see below)

Pregnancy

All pregnant women (including those who may need to self-isolate for a period)

NICE Guidelines* identify the following groups at risk of hypertension in pregnancy:
One of  the following risk factors:
  • hypertensive disease during a previous pregnancy
  • chronic kidney disease
  • autoimmune disease (e.g. systemic lupus erythematosus orantiphospholipid syndrome)
  • type 1 or type 2 diabetes
Two or more of  the following risk factors:
  • first pregnancy
  • age 40 years or older
  • pregnancy interval of more than 10 years
  • body mass index (BMI) of 35 kg/m2 or more family history of pre-eclampsia
  • multi-fetal pregnancy

*NICE guideline [NG133] “Hypertension in pregnancy:diagnosis and management” published June 2019: www.nice.org.uk/guidance/ng133

Benefits

Improves care
Improves care

Provides women with advice about blood pressure levels.

Gives control
Gives control

Self- monitoring gives pregnant women greater control of their pregnancy care while potentially reducing the need for face-to-face clinic visits

Provides reassurance
Provides reassurance

Helps mums-to-be self-monitor blood pressure to protect themselves and their baby.

Easy, accurate monitoring
Easy, accurate monitoring

Provides an easy to use and uniform monitoring system for healthcare professionals.

Increases safety
Increases safety

Reduces face-to-face contact to reduce risk associated with COVID-19 infection.

Secure
Secure

All patient data is anonymised, securely stored on the cloud as a completely isolated instance with rigorous data security and privacy measures.

BPm-Health is classified as a Medical Device and is registered as such with the UK National Competent Authority (MHRA)

Note : Not all Sensyne Health products are available inall geographies, for further information contact head office. 

FAQs

What is BPm-Health?
Who is BPm-Health intended for?
How do pregnant women access and use the app?
How does the system help maternity services?
How will BPm-Health help the NHS during and after the pandemic?
What are the main features of the app?
How much does BPm-Health cost?
Does BPm-Health store any patient sensitive data?
What is the background to the development of BPm-Health?
What clinical guidelines support the use of BPm-Health?
What is the clinical science behind BPm-Health?
Can BPm-Health be used without needing to download an app?
Does BPm-Health provide a patient diagnosis? 
Who can see the data entered into BPm-Health? 
What does anonymised data mean?
How do you protect personal and healthcare data? 

References

  1. McManus RJ, Mant J,Franssen M, Nickless A, Schwartz C, Hodgkinson J, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet. 2018; 391(10124):949-59.

  2. McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet. 2010; 376(9736):163-72.

  3. McManus RJ, Mant J, Haque MS, Bray EP, Bryan S, Greenfield SM, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA. 2014 ;312(8):799-808.

  4. Pealing LM, Tucker KL, Mackillop LH, Crawford C, Wilson H, Nickless A, et al. A randomised controlled trial of blood pressure self-monitoring in the management of hypertensive pregnancy. OPTIMUM-BP: A feasibility trial. Pregnancy Hypertens. 2019; 18:141-9.

  5. Cairns AE, Tucker KL, Leeson P, Mackillop LH, Santos M, Velardo C, et al. Self-Management of Postnatal Hypertension: The SNAP-HT Trial. Hypertension. 2018.

  6. Tucker KL, Taylor KS, Crawford C, Hodgkinson JA, Bankhead C, Carver T, et al. Blood pressure self-monitoring in pregnancy: examining feasibility in a prospective cohort study. BMC Pregnancy Childbirth. 2017; 17(1):442.

  7. Hinton L, Tucker KL, Greenfield SM, Hodgkinson JA, Mackillop L, McCourt C, et al.Blood pressure self-monitoring in pregnancy (BuMP) feasibility study; a qualitative analysis of women's experiences of self-monitoring. BMC Pregnancy Childbirth. 2017; 17(1):427.

  8. Grant S, Hodgkinson J, Schwartz C, Bradburn P, Franssen M, Hobbs FR, et al. Using mHealth for the management of hypertension in UK primary care: an embedded qualitative study of the TASMINH4 randomised controlled trial. Br J Gen Pract. 2019; 69(686):e612-e20.

  9. Jones MI, Greenfield SM, Bray EP, Baral-Grant S, Hobbs FD, Holder R, et al. Patients' experiences of self-monitoring blood pressure and self-titration of medication: the TASMINH2 trial qualitative study. Br J Gen Pract. 2012; 62(595):e135-e42.